Tecla M Temu1, Jerry S Zifodya2, Stephen J Polyak3, Jessica Wagoner3, Celestine N Wanjalla4, Sarah Masyuko1,5,6, Jerusha Nyabiage1, John Kinuthia6, Gerald S Bloomfield7, Stephanie T Page8, Carey Farquhar1,8,9. 1. Department of Global Health, University of Washington, Seattle, Washington. 2. Department of Medicine, Tulane University, New Orleans, Louisiana. 3. Department of Laboratory Medicine, University of Washington, Seattle, Washington. 4. Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA. 5. Ministry of Health. 6. Kenyatta National Hospital, Nairobi, Kenya. 7. Department of Medicine and Duke Global Health Institute, Duke University, Durham, North Carolina. 8. Department of Medicine. 9. Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Abstract
INTRODUCTION: Markers of monocyte/macrophage activation and vascular inflammation are associated with HIV-related cardiovascular diseases (CVD) and mortality. We compared these markers among African people living with HIV (PLWH) and HIV-negative adults, and examined risk factors associated with elevated biomarkers (>75th percentile) in PLWH on antiretroviral therapy (ART). DESIGN: Cross-sectional study. METHODS: We measured serum concentrations of a gut integrity biomarker (intestinal-fatty acid binding protein), monocyte/macrophage activation biomarkers (soluble CD14 and CD163), and vascular inflammation biomarkers [soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular adhesion molecule 1 (sVCAM-1)]. We assessed the relationship of these inflammatory parameters with HIV, using logistic regression adjusting for traditional CVD risk factors. RESULTS: Among the 541 participants, median age was 43 years and half were female. Among 275 PLWH, median CD4 T-cell count and duration of ART use was 509 cells/μl and 8 years, respectively. PLWH had significantly higher prevalence of elevated inflammatory biomarkers compared with HIV-negative individuals even after adjustment for traditional CVD risk factors. Compared with individuals without HIV, the prevalence of elevated biomarkers was highest among persons with detectable viral load and CD4 T-cell counts 200 cells/μl or less. In a subanalysis among PLWH, nadir CD4 T-cell count 200 cells/μl or less was associated with elevated soluble CD14 (sCD14); dyslipidemia with elevated sCD14, sICAM-1, and sVCAM-1; and overweight/obesity with reduced sCD14. Longer ART exposure (>4 years) was associated with reduced sVCAM-1 and sICAM-1. CONCLUSION: HIV and not traditional CVD risk factors is a primary contributor of monocyte/macrophage activation and inflammation despite ART. Anti-inflammatory therapies in addition to ART may be necessary to reduce these immune dysregulations and improve health outcomes of African PLWH.
INTRODUCTION: Markers of monocyte/macrophage activation and vascular inflammation are associated with HIV-related cardiovascular diseases (CVD) and mortality. We compared these markers among African people living with HIV (PLWH) and HIV-negative adults, and examined risk factors associated with elevated biomarkers (>75th percentile) in PLWH on antiretroviral therapy (ART). DESIGN: Cross-sectional study. METHODS: We measured serum concentrations of a gut integrity biomarker (intestinal-fatty acid binding protein), monocyte/macrophage activation biomarkers (soluble CD14 and CD163), and vascular inflammation biomarkers [soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular adhesion molecule 1 (sVCAM-1)]. We assessed the relationship of these inflammatory parameters with HIV, using logistic regression adjusting for traditional CVD risk factors. RESULTS: Among the 541 participants, median age was 43 years and half were female. Among 275 PLWH, median CD4 T-cell count and duration of ART use was 509 cells/μl and 8 years, respectively. PLWH had significantly higher prevalence of elevated inflammatory biomarkers compared with HIV-negative individuals even after adjustment for traditional CVD risk factors. Compared with individuals without HIV, the prevalence of elevated biomarkers was highest among persons with detectable viral load and CD4 T-cell counts 200 cells/μl or less. In a subanalysis among PLWH, nadir CD4 T-cell count 200 cells/μl or less was associated with elevated soluble CD14 (sCD14); dyslipidemia with elevated sCD14, sICAM-1, and sVCAM-1; and overweight/obesity with reduced sCD14. Longer ART exposure (>4 years) was associated with reduced sVCAM-1 and sICAM-1. CONCLUSION: HIV and not traditional CVD risk factors is a primary contributor of monocyte/macrophage activation and inflammation despite ART. Anti-inflammatory therapies in addition to ART may be necessary to reduce these immune dysregulations and improve health outcomes of African PLWH.
Authors: Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Torsten B Neilands; Colleen F Kelley; Peter W Hunt; Rebecca Hoh; Jeffrey M Linnen; Jeffrey N Martin; Michael P Busch; Steven G Deeks Journal: AIDS Date: 2010-10-23 Impact factor: 4.177
Authors: João F P Rezer; Stephen A Adefegha; Assis Ecker; Daniela F Passos; Renata S P Saccol; Tatiana M D Bertoldo; Daniela B R Leal Journal: Microb Pathog Date: 2017-11-27 Impact factor: 3.738
Authors: Robert C Kaplan; Alan L Landay; Howard N Hodis; Stephen J Gange; Philip J Norris; Mary Young; Kathryn Anastos; Phyllis C Tien; Xiaonan Xue; Jason Lazar; Christina M Parrinello; Lorie Benning; Russell P Tracy Journal: J Acquir Immune Defic Syndr Date: 2012-08-01 Impact factor: 3.731
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Mark J Siedner; Mwebesa Bosco Bwana; Stephen Asiimwe; Gideon Amanyire; Nicholas Musinguzi; Jose Castillo-Mancilla; Russell P Tracy; Ingrid T Katz; David R Bangsberg; Peter W Hunt; Catherine Orrell; Jessica E Haberer Journal: J Infect Dis Date: 2019-08-30 Impact factor: 5.226
Authors: Anoop S V Shah; Dominik Stelzle; Kuan Ken Lee; Eduard J Beck; Shirjel Alam; Sarah Clifford; Chris T Longenecker; Fiona Strachan; Shashwatee Bagchi; William Whiteley; Sanjay Rajagopalan; Shyamasundaran Kottilil; Harish Nair; David E Newby; David A McAllister; Nicholas L Mills Journal: Circulation Date: 2018-09-11 Impact factor: 29.690
Authors: Natalie Castell; Selena M Guerrero-Martin; Leah H Rubin; Erin N Shirk; Jacqueline K Brockhurst; Claire E Lyons; Kevin M Najarro; Suzanne E Queen; Bess W Carlson; Robert J Adams; Craig N Morrell; Lucio Gama; David R Graham; Christine Zink; Joseph L Mankowski; Janice E Clements; Kelly A Metcalf Pate Journal: Psychosom Med Date: 2022-09-07 Impact factor: 3.864
Authors: K M Emanuel; K Runner; Z D Brodnik; B M Morsey; B G Lamberty; H S Johnson; A Acharya; S N Byrareddy; R A España; H S Fox; P J Gaskill Journal: iScience Date: 2022-04-06